文献速递眼底病与葡萄膜炎

地塞米松玻璃体内植入剂治疗初治糖尿病性黄斑水肿:AUSSIEDEX研究结果

Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study.
PubMed 文献 · Br J Ophthalmol · 2021-08-25

AUSSIEDEX研究为开放标签、前瞻性、4期真实世界研究,纳入初治或抗VEGF无应答的糖尿病性黄斑水肿患眼,其中57只初治眼接受地塞米松植入剂0.7 mg单药治疗。52周时平均最佳矫正视力提高3.4个字母(p=0.042),平均中央视网膜厚度下降89.6 µm(p<0.001),平均注射2.5次,未报告新的安全性问题。

要点

  • 初治糖尿病性黄斑水肿眼52周平均BCVA提高3.4字母,CRT下降89.6 µm。
  • 平均注射2.5次,20.0%患眼需降眼压药物,无滤过手术或严重治疗相关不良事件。

核心结论

  • 地塞米松玻璃体内植入剂0.7 mg单药治疗初治糖尿病性黄斑水肿,52周时显著改善中央视网膜厚度和最佳矫正视力,未发现新的安全性问题。

研究设计与样本

  • 开放标签、前瞻性、4期真实世界研究,纳入假晶体眼和计划白内障手术的晶体眼,初治或抗VEGF无应答,不按基线BCVA或CRT排除。
  • AUSSIEDEX研究共纳入200只眼,其中57只为初治眼。
  • 基线后首次注射地塞米松植入剂,允许≥16周间隔重复注射,第16周和第52周访视强制。

主要发现

  • 初治亚组基线平均BCVA为58.8个字母,基线平均CRT为418.6 µm。
  • 初治亚组52周平均BCVA较基线提高3.4个字母(p=0.042),平均CRT较基线下降89.6 µm(p<0.001)。
  • 初治亚组平均注射2.5次,第16周平均CRT较基线下降55.8 µm(p<0.001)。
  • 最常见不良事件为眼压升高,20.0%患眼需降眼压药物,1例因眼压升高停药,无患眼需滤过手术,未报告严重治疗相关眼部不良事件。

关键数值与推荐

  • 初治亚组52周平均BCVA变化3.4字母(p=0.042),平均CRT变化-89.6 µm(p<0.001)。
  • 第16周平均CRT变化-55.8 µm(p<0.001)。
  • 20.0%患眼需降眼压药物,1例因眼压升高停药,无滤过手术。

临床怎么用

  • 对于初治糖尿病性黄斑水肿,地塞米松植入剂0.7 mg单药可考虑作为治疗选择,需监测眼压并按需降眼压治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME). METHODS: The open-label, prospective, phase 4, real-world study included pseudophakic eyes and phakic eyes scheduled for cataract surgery that were treatment-naïve or non-responsive to antivascular endothelial growth factors. No eyes were excluded based on baseline best-corrected visual acuity (BCVA) or central subfield retinal thickness (CRT). After the initial DEX injection at the baseline visit, reinjection was permitted at ≥16-week intervals. Week-16 and week-52 visits were mandatory. Primary endpoints were changes in mean BCVA and CRT from baseline to 52 weeks. RESULTS: Of 200 eyes enrolled in the AUSSIEDEX study, 57 were treatment-naïve. Baseline mean BCVA was 58.8 letters and baseline mean CRT was 418.6 µm; changes in mean BCVA and CRT from baseline to 52 weeks in this subgroup were 3.4 letters (p=0.042) and -89.6 µm (p<0.001), respectively, with a mean 2.5 injections. The change in mean CRT from baseline was -55.8 µm at week 16 (p<0.001). The most common adverse event was increased intraocular pressure (IOP), with 20.0% of eyes requiring IOP-lowering medication. One patient was discontinued due to increased IOP. No eyes required filtration surgery. No serious, treatment-related ocular adverse events were reported. CONCLUSION: In this largest prospective, real-world study of DEX monotherapy for DME to date, DEX significantly improved CRT and BCVA at 52 weeks in treatment-naïve eyes, without new safety concerns, supporting DEX use in treatment-naïve DME. TRIAL REGISTRATION NUMBER: NCT02731911.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fraser-Bell S, Kang HK, Mitchell P, et al. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. Br J Ophthalmol. 2021. PMID: 34433549. doi:10.1136/bjophthalmol-2021-319070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。